Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Arai H, et al. Among authors: shimokawa m. Cancer Med. 2024 Apr;13(7):e7107. doi: 10.1002/cam4.7107. Cancer Med. 2024. PMID: 38591098 Free PMC article. Clinical Trial.
[Studies on drug interaction of combined drug II. Interaction among isopropylantipyrine, phenacetin, allylisopropylacetylurea and caffeine on the plasma level of isopropylantipyrine and phenacetin in dogs (author's transl)].
Nakajima T, Okada T, Takeuchi S, Shimokawa M, Kuruma I. Nakajima T, et al. Among authors: shimokawa m. Yakugaku Zasshi. 1977 Jun;97(6):607-12. doi: 10.1248/yakushi1947.97.6_607. Yakugaku Zasshi. 1977. PMID: 925850 Japanese. No abstract available.
CD155 Expression in Early-stage Lung Adenocarcinoma.
Matsudo K, Takada K, Kinoshita F, Hashinokuchi A, Nagano T, Akamine T, Kohno M, Takenaka T, Shimokawa M, Oda Y, Yoshizumi T. Matsudo K, et al. Among authors: shimokawa m. Ann Thorac Surg. 2024 Jun 18:S0003-4975(24)00476-4. doi: 10.1016/j.athoracsur.2024.05.042. Online ahead of print. Ann Thorac Surg. 2024. PMID: 38901626
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50].
Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Takeda M, et al. Among authors: shimokawa m. Lung Cancer. 2024 Jun 17:107852. doi: 10.1016/j.lungcan.2024.107852. Online ahead of print. Lung Cancer. 2024. PMID: 38890056 No abstract available.
Assessing the ability of the Cancer and Aging Research Group tool to predict chemotherapy toxicity in older Japanese patients: A prospective observational study.
Uchiyama M, Miyazaki M, Hayashi T, Shimokawa M, Nakano T, Kakimoto H, Takaki S, Fukue H, Inoue T, Inoue R, Mashima K, Kawata S, Sumi Y, Igarashi Y, Kamimura H, Imakyure O, Matsuo K. Uchiyama M, et al. Among authors: shimokawa m. J Geriatr Oncol. 2024 Jun 7;15(6):101814. doi: 10.1016/j.jgo.2024.101814. Online ahead of print. J Geriatr Oncol. 2024. PMID: 38851083 Free article.
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Kodama T, Imajima T, Shimokawa M, Otsuka T, Kawahira M, Nakazawa J, Hori T, Shibuki T, Arima S, Ido A, Miwa K, Okabe Y, Koga F, Ueda Y, Kubotsu Y, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Sakai K, Oda H, Kawahira M, Arita S, Honda T, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Shirakawa T, Mizuta T, Mitsugi K. Kodama T, et al. Among authors: shimokawa m. Sci Rep. 2024 May 30;14(1):12422. doi: 10.1038/s41598-024-63172-y. Sci Rep. 2024. PMID: 38816500 Free PMC article.
New predictors of microvascular invasion for small hepatocellular carcinoma ≤ 3 cm.
Fukushima R, Harimoto N, Okuyama T, Seki T, Hoshino K, Hagiwara K, Kawai S, Ishii N, Tsukagoshi M, Igarashi T, Araki K, Tomonaga H, Higuchi T, Shimokawa M, Shirabe K. Fukushima R, et al. Among authors: shimokawa m. Int J Clin Oncol. 2024 May 20. doi: 10.1007/s10147-024-02553-9. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38769190
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K. Nosaki K, et al. Among authors: shimokawa m. Int J Clin Oncol. 2024 May 17. doi: 10.1007/s10147-024-02543-x. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38758397
440 results